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Abstract
Objective—Users of hormonal long-acting reversible contraception (LARC) report weight gain 
as a side effect, but few studies have assessed body composition change among LARC users. We 
evaluated weight and body composition of healthy women using the levonorgestrel intrauterine 
system (LNG-IUS), copper intrauterine device (copper IUD), or etonogestrel implant (ENG 
implant). We hypothesized that weight gain and body composition over 12 months would not 
differ between copper IUD, LNG-IUS, and ENG implant users.
Study Design—We performed a prospective cohort study of a subgroup of women enrolled in 
the Contraceptive CHOICE Project who initiated the LNG-IUS, copper IUD, or ENG implant. 
Inclusion criteria included lack of metabolic and eating disorders, or change in body weight of 
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more than 5% in the six months before enrollment. We measured changes in weight and body 
composition (body fat percentage, total body fat mass, total lean mass, and total body mass) in 
women who continued their method for 12 months.
Results—We analyzed data from 149 participants: 85 LNG-IUS users, 31 copper IUD users, and 
33 ENG implant users. The mean age was 25.9 years, 56.4% were white, 82.5% had some college 
education, and 67.6% were nulliparous. Although lean body mass increased over 12 months in 
LNG-IUS and copper IUD users but not in ENG implant users, changes in body weight and body 
composition did not differ between the groups. In the adjusted model, black race was associated 
with change in total body mass (P < 0.05).
Conclusions—Among those who continued the method for 12 months, changes in body weight 
and composition did not differ between copper IUD, LNG-IUS, and ENG implant users.
Keywords
Body composition; weight; contraception; levonorgestrel intrauterine system; etonogestrel 
subdermal implant; copper intrauterine device
1. Introduction
Long-acting reversible contraceptive (LARC) methods are highly effective, safe, and cost-
effective. LARC methods include the copper intrauterine device (copper IUD), the 
levonorgestrel intrauterine system (LNG-IUS), and the subdermal etonogestrel-releasing 
implant (ENG implant). These methods are 20-fold more effective than oral contraceptive 
pills, patch, and ring, and provide long-term protection against unintended pregnancy [1,2,3]
Early discontinuation limits the effectiveness of contraceptives. Several studies have 
indicated that women may discontinue hormonal contraception as a result of a commonly 
perceived side effect of weight gain [4–6]. Changes in weight are most consistently reported 
in users of depot medroxyprogesterone acetate (DMPA) [7,8], but changes have also been 
reported in LARC users. Nault et al. found that more than 30% of LNG-IUS and ENG 
implant users perceived weight gain, and Dickerson and colleagues noted that 12% of LNG-
IUS users and 31% of ENG implant users reported weight gain as a side effect [6,9].
Only a few studies have evaluated changes in body composition in LARC users. Two 
prospective studies evaluated body composition by dual energy X-ray absorptiometry 
(DXA) in women between 18 and 46 years of age. These studies showed that body fat 
percentage increased in LNG-IUS and ENG implant users and decreased in copper IUD 
users [10,11].
The primary aim of this study was to evaluate changes in body composition (body fat 
percentage, total body fat mass [g], total lean mass [g], total body mass [kg]) in users of the 
LNG-IUS and ENG implant over 12 months of continuous use and compare the findings to 
users of the copper IUD. We chose copper IUD users as the reference group because it is a 
non-hormonal LARC method, whereas the LNG-IUS and ENG implant are progestin-only 
methods. Our secondary aim was to assess physical activity and eating behaviors. We 
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hypothesized that changes in weight gain and body composition or weight over 12 months 
would not differ between the three groups.
2. Materials and Methods
We conducted a prospective cohort substudy of the Contraceptive CHOICE Project 
(CHOICE). CHOICE provided no-cost reversible contraceptive methods to more than nine 
thousand women in the St. Louis region between 14 and 45 years of age and followed them 
for 2–3 years. Eligibility criteria for CHOICE included English or Spanish speaking, 
sexually active or planning to become sexually active with a male partner, and willingness to 
start a new contraceptive method [12]. After receiving tier-based counseling based on 
method effectiveness, participants could choose any FDA-approved reversible contraceptive 
method [13].
Between December 2010 and July 2013, CHOICE participants between 18 and 45 years of 
age who enrolled at our university and chose the LNG-IUS (Mirena®, Bayer 
Pharmaceuticals, Wayne, NJ), the copper IUD (ParaGard®, Barr Pharmaceuticals, Montvale, 
NJ), or the ENG contraceptive implant (Implanon®, Schering Corporation, Kenilworth, NJ) 
were approached for interest in participation in this sub-study. Participants had to be willing 
to undergo a dual-energy X-ray absorptiometry (DXA) bone densitometry scan (GE Lunar 
iDXA system, version:13.31, WI, USA) and return for in-person follow-up visits at 6 and 12 
months. Exclusion criteria for this study included the following: 1) known metabolic or 
eating disorders that can affect body weight; 2) 5% or greater change in body weight in the 
six months before enrollment; 3) current use of antidepressants, antipsychotics, or oral 
glucocorticoids; and 4) currently breastfeeding. We excluded data of women from the 
analysis if they discontinued their contraceptive method before the 12-month time point. We 
obtained approval from the Washington University School of Medicine Human Research 
Protection Office for this substudy (#201105463); all women signed an informed consent 
form.
After screening, participants completed three in-person visits in our university: at baseline, 
at 6-months, and at 12 months. At enrollment and the 12-month visit, we evaluated weight, 
height, eating behavior and physical activity and performed a DXA scan. At the 6-month 
visit, we evaluated weight, height, eating behavior, and physical activity. We compensated 
the participants with a $50 gift card at enrollment and at 12 months, and a $25 gift card at 6 
months.
Because of the possibility that low-dose progestin is associated with changes in weight and 
body composition, we considered women who received the copper IUD, which is non-
hormonal, as the referent group. We analyzed the change of weight and body composition 
over 12 months of continuous use of the same contraceptive method. Additionally, we 
assessed baseline demographic characteristics of discontinuers and compared these 
characteristics to continuers. Our primary outcomes were the mean changes in total body 
mass (kg), body fat percentage, total body fat mass (g), and total lean mass (g) over time of 
LNG-IUS, ENG implant, and copper IUD users. We also evaluated weight, body mass index 
(BMI), physical activity, and eating behavior as our secondary outcomes.
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2.1 Definition of variables
Independent (exposure) variables were the contraceptive methods: LNG-IUS, copper IUD, 
or ENG implant. The dependent variables (outcomes of interest) were weight and body 
composition. We measured weight and height on the same scale at the beginning of the study 
and after 12 months of continuous contraceptive use. Trained technicians used DXA to 
quantitate total body tissue and evaluate whole-body composition [14,15] (body fat 
percentage, total body fat mass [g], total lean mass [g], and total body mass [kg]) at baseline 
and after 12 months. The coefficients of variation for the total body percentage fat, lean 
mass, and fat mass measurements were 0.8%, 0.5%, and 0.8%, respectively. We calculated 
the body mass index as [weight (kg)/(height (m)2]. We used the Seven-Day Physical Activity 
Recall questionnaire [16] to obtain frequency, intensity, time, and type of physical activities 
at the beginning of the study and after 12 months. Self-reported recall focused on 
occupational, household, and sports or recreation activities. The average energy expenditure 
for each activity for the seven days preceding the interviews was converted to metabolic 
equivalent tasks (METs) as described by Sallis [16].
We used the self-administered Three-Factor Eating Questionnaire (TFEQ) to assess eating 
behaviors. The TFEQ contains 51 questions and measures three domains of human eating 
behavior: ‘cognitive restraint of eating’ (Factor I - 21 questions), ‘disinhibition’ (Factor II–
16 questions), and ‘hunger’ (Factor III–14 questions). Each question is attributed a score of 
0 or 1 points. The possible scores for Factors I, II, and III are 0–21, 0–16, and 0–14, 
respectively [17]. The TFEQ is often used in eating behavior research and is validated for 
use in women [18].
2.2 Statistical analysis
We compared demographic, socioeconomic, and reproductive characteristics between the 
groups at baseline by using Chi-square or Fisher`s exact test for categorical variables. We 
compared the means (± standard deviation [s.d.]) of weight, BMI, physical activity, eating 
behavior, and body composition at baseline and 12 months by one-way univariate ANOVA. 
For variables with P<.05, we performed the Bonferroni (Dunn) t-test post-hoc test. 
Additionally, we used paired t-tests for each contraceptive method to investigate the mean 
variations (baseline mean measurements subtracted from the 12-month mean measurements) 
of weight, BMI, physical activity, eating behavior, and body composition of the participants 
who had both baseline and 12 months data. We performed univariate and multivariable 
linear regression to identify characteristics associated with the mean change in total body 
mass (kg) after 12 months. We used a simple linear regression model to compare total body 
mass change between LNG-IUS and copper IUD users and between ENG implant and 
copper IUD users. We defined significance level as P < 0.05 and used SAS (Statistical 
Analysis System, version 9.4; SAS Institute Inc. Cary, NC, USA) for all statistical analyses.
For our sample size calculation, we assumed a mean change of +0.6 kg in copper IUD users 
over 12 months; this was the mean weight change in U.S women over this period reported 
by the National Health and Nutrition Examination Survey [19]. Among users of the LNG-
IUS and the ENG implant, we assumed a mean weight gain of 2.0 kg. To perform analysis of 
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variances, and considering a significance level of 5% and power of 80%, we estimated a 
requirement of 73 women in each group.
3. Results
We enrolled 232 women into this substudy. Of these, 149 women used their baseline 
contraceptive method continuously for 12 months and were included in our analysis: 85 
LNG-IUS users, 33 ENG implant users, and 31 copper IUD users (see Figure 1).
Table 1 shows age, weight, BMI, physical activity, eating behavior, body composition, and 
demographic characteristics at baseline stratified by contraceptive method of the participants 
whose data we analyzed in our substudy. Of the total sample, the mean (± s.d.) age was 25.9 
(5.7) years, more than 50.0% of users self-identified as white, 80.0% had some college or 
graduate school, and 60.0% were nulliparous. We found no significant differences in 
demographic characteristics of the participants who continued their methods and completed 
the 12-month follow-up and those who did not. In the group who discontinued the 
contraceptive method, the mean age was 25.9 (5.7) years, 52.0% of users self-identified as 
white, 65.7% had some college or high school, and 61.2% were nulliparous. We found no 
statistically significant difference in the weights or body fat percentage when we compared 
participants who continued use for 12 months to those that discontinued use. Additionally, 
there was no significant difference in the BMI at 6 months between the continued and 
discontinued groups.
Table 2 contains the body weight, BMI, physical activity, eating behavior, and body 
composition measures for continuous users at baseline and 12 months. Changes in weight, 
BMI, eating behavior, and body composition over 12 months of continuous use did not differ 
between the three groups. The ENG implant users reported higher metabolic expenditure 
(physical activity) than did the copper IUD users at 12 months (per day: difference in means 
of ENG implant and copper IUD=1.67, 95%CI: 0.006–3.20, P<.05; per week: difference in 
means of ENG implant and copper IUD=11.24, 95%CI: 0.042–22.45, P<.05). Additionally, 
we found a mean increase of 0.5, 0.4, and 0.1 kg of body weight in users of LNG-IUS, 
copper IUD, and ENG implant, respectively, after 12 months of continuous use. BMI and 
physical activity did not change over 12 months in any of the groups. Cognitive restraint of 
eating, cognitive disinhibition, and subjective appetite decreased in LNG-IUS (P<.001), 
copper IUD (P<.005) and ENG implant (P<.05) users. Lean body mass increased between 
baseline and 12 months in LNG-IUS users (+ 464.7 g; P=.03) and copper IUD users 
(+ 788.7 g; P=.03).
We provide univariate and multivariable linear regression models with the mean of total 
body mass (kg) change at 12 months in Table 3. Contraceptive method was not associated 
with change in body mass at 12 months in either the unadjusted or adjusted models. In both 
models, black race was associated with change in total body mass over time.
4. Discussion
In this prospective substudy, we found that changes in weight, BMI, and body composition 
among those with 12 months of continuous use did not differ between users of the LNG-
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IUS, the ENG implant, and the copper IUD. Additionally, in both the unadjusted and 
adjusted linear regression models, black race was associated with change in total body mass 
at 12 months.
The LNG-IUS and ENG implant are progestin-only contraceptive methods. The LNG-IUS is 
a 20mcg/day levonorgestrel-releasing intrauterine system, and the ENG implant is a single-
rod of 68mg etonogestrel-releasing subdermal implant. The systemic serum concentration of 
progestin in the LNG-IUS is lower than the ENG implant. Pain and irregular bleeding are 
the major reasons for their early discontinuation [6,20]. Weight gain has been a reported 
reason for method discontinuation by 5% to 20% of ENG implant users [6,20] and 15% to 
20% of LNG-IUS users [6]. In our study, we observed a mean increase of 0.5 and 0.1 kg in 
users of the LNG-IUS and ENG implant, respectively, after 12 months of continuous use. In 
the Cochrane systematic review, Lopez and colleagues reported mean weight gain of less 
than 2 kg in users of progestin-only contraceptive methods [21]. In contrast, two prospective 
studies showed a weight gain of 2.9 kg in LNG-IUS users [10] and 4.1 kg in ENG implant 
users [11] after 12 months of continuous use.
Regarding body composition, two other prospective studies reported differences in body 
composition changes over 12 months. In a study of 75 ENG implant users and 75 copper 
IUD users, Modesto and colleagues found that women using the ENG implant had a 2% 
increase in body fat and a 2.4 kg increase in fat mass, whereas copper IUD users had no 
significant increase in body fat or fat mass [11]. Dal’Ava et al. studied 76 LNG-IUS users 
and 76 copper IUD users, matched by age and baseline body mass index, and observed a 
2.5% increase in body fat in LNG-IUS users but no significant increase in body fat in copper 
IUD users [10]. In our comparison within each contraceptive method group, we noted that 
lean body mass increased in LNG-IUS and copper IUD users. However, our small sample 
size in the copper IUD and ENG implant groups provided limited power to detect a 
difference. We observed an association between black race and increased body mass over 
time. Other prospective studies of adult and adolescent users of DMPA or LARC 
contraceptives methods (LNG-IUS, ENG implant, and copper IUD) also found an 
association between black race and weight gain [7,22].
After 12 months of use, ENG implant users reported a greater increase of metabolic 
expenditure (physical activity) than LNG-IUS and copper IUD users. We found one other 
prospective study that evaluated body composition and lifestyle habits (smoking, alcohol, 
and physical activity) and compared 20 DMPA users and 20 copper IUD users, matched by 
age and body mass index. This report dichotomized physical activity as “yes” (aerobic 
activity ≥ 150 min/week) or “no” (aerobic activity < 150 min/week or none at all). The 
investigators reported no statistical differences between lifestyle habits and these 
contraceptives groups at baseline and 12 months [23]. It is possible that our findings of 
increased self-reported physical activity are due to social desirability bias [24].
We noted that self-reported eating behavior scores decreased in each contraceptive group 
after 12 months of use. When we searched the medical literature by using MEDLINE, 
EMBASE, POPLINE, and Scopus (search terms: “body weight changes AND contraceptive 
agents, female”; “body weight AND contraceptive methods”; “eating behavior AND 
de Nazaré Silva dos Santos et al. Page 6
Contraception. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
contraception”), we found no published studies evaluating eating behavior using the TFEQ 
in LARC users. The TFEQ is a validated questionnaire used in clinical research to assess 
eating behaviors over time in women [18]. Higher scores indicate higher probability of 
restrained eating, disinhibited eating, and predisposition to hunger. Scores of cognitive 
disinhibition are directly associated with weight change and total body mass; therefore, 
higher scores on Factor II reveal higher predisposition to weight gain [17]. Studies of adult 
contraceptive users of DMPA and oral contraceptive pills have assessed appetite by using 
“no/yes” questions [8,25]. However, these studies did not evaluate whether changes in eating 
behaviors over time differed between contraceptive groups. Bonny and colleagues, using the 
same TFEQ methodology, reported higher appetite score in black adolescent DMPA users 
than in white DMPA users at six months of use; restrained and disinhibited eating were 
predictors of weight gain in black adolescents. Additionally, these investigators showed an 
increase of weight and body fat percentage in black subjects [7]. We have no clear 
explanation for the reported decrease in eating behavior over time in our cohort other than 
the possibility of social desirability bias [26,27].
A woman may believe that her contraceptive method is responsible for weight gain [6,9] and 
thus choose to discontinue the method [20]. In our study, we excluded from analysis women 
who discontinued their contraceptive method before 12 months. We did not collect reasons 
for discontinuation and thus do not know whether they discontinued because of real or 
perceived weight gain. However, this group had similar baseline characteristics as those who 
continued the same contraceptive method over 12 months.
In our substudy, we enrolled healthy adult women from a single geographic region who had 
no eating disorder history or important weight change in the recent past. The principal 
strengths of our study are prospective design in a contemporary cohort of LARC users, use 
of validated measures of eating behavior and body composition, and a multivariable analysis 
to attempt to control for confounding. However, key limitations include loss of more than 
one-third of participants because of method discontinuation, small sample size of ENG 
implant and copper IUD users, and lack of randomization. The generalizability of our 
findings are limited as our study only included participants who used their method 
continuously for 12 months. Additionally, we informed the participants that the study was 
evaluating change in body composition over time; this may have led to increased attention to 
physical activity and eating behavior, or at least reporting desirable behaviors.
5. Conclusion
In a subgroup of CHOICE participants who continued their LARC method for 12 months, 
we found that changes in weight and body composition over time did not differ between 
users of LNG-IUS, ENG implant, or copper IUD. Additionally, there was no significant 
difference in the BMI at 6 months between the continued and discontinued groups. We noted 
that black race was associated with an increase in body mass. Our results add to the body of 
literature regarding weight and body composition changes with contraceptive use. 
Additional prospective studies with a sufficient number of subjects in each contraceptive 
group are necessary to confirm or refute our findings.
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Implications statement
Changes in body weight and composition over 12 months did not differ between copper 
IUD users and LNG-IUS and ENG implant users among those with 12 months of 
continuous use.
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Figure 1. 
Analytic sample selection flow chart
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Table 3
Univariate and multivariable linear regression models of characteristics associated with DXA total body mass 
(kg) change at 12 months.
Characteristics Mean total body mass Change (beta) 95% CI
Unadjusted Models
Age −0.2 −0.38,−0.01
BMI at baseline −0.01 −0.15,0.13
Race
 White/Others Ref
 Black 2.68 0.54,4.83
Contraceptive method
 Copper IUD Ref
 LNG-IUS −0.17 −2.87,2.52
 ENG implant −0.47 −3.64,2.70
Parity
 0 Ref
 1 2.55 −0.83,5.95
 2 or more −2.37 −5.02,0.28
Education
 High school or less Ref
 Some college −0.004 −3.18,3.17
 College graduate or more 0.05 −3.15,3.27
Physical activity at baseline
 METs/day −0.07 −0.33,0.20
Eating Behavior at baseline
 Restrained eating −0.22 −0.48,0.05
 Disinhibited eating −0.36 −0.73,0.01
 Appetite −0.52 −0.93,−0.10
Adjusted Model
Age −0.18 −0.36,−0.00
Race
 White/Others Ref
 Black 2.59 0.47,4.69
Contraceptive method
 Copper IUD Ref
 LNG-IUS −0.31 −2.88,2.26
 ENG implant −0.5 −3.53,2.52
Eating Behavior at baseline
 Appetite −0.35 −0.83,0.14
CI: confidence interval; METs: metabolic equivalent intensity levels; LNG-IUS: levonorgestrel-releasing intrauterine system; LNG-IUS: 
levonorgestrel-releasing intrauterine system; ENG implant: etonogestrel implant; Copper IUD: copper intrauterine device
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